SAINTE-FOY, QUEBEC--(MARKET WIRE)--Jun 13, 2006 -- Bioxel Pharma Inc. (TSX VENTURE:BIP.V - News), a leading manufacturer and supplier of taxane APIs and developer of targeted oncology drugs, is pleased to announce that six new generic pharmaceutical companies will list Bioxel's paclitaxel API in their registration dossier; bringing to eight the number of EU countries for which its paclitaxel API can be used in commercial generic drugs.
